GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Head to head

Fifty 410 vs Noom Med: Pricing, Evidence and What Neither Discloses

We will not name a cheaper provider here. At least one of these figures is an advertised starting price or is reported to rise with dose, so $133 against $199 compares a price paid for about four weeks with one that may not hold either.

Direct answer

On their own pages, read November 20, 2026 or later, Fifty 410 lists $199 month to month and $149.50 at its lowest (8-week program $299); Noom Med lists $299 month to month. Month to month, like for like, Fifty 410 costs $100 a month less. On our written v4.1 scoring guide, Fifty 410 scores 65/100 (#12 of 22) and Noom Med scores 45/100 (#20 of 22).

Answer last reviewed:

The short answer

We will not name a cheaper provider here. At least one of these figures is an advertised starting price or is reported to rise with dose, so $133 against $199 compares a price paid for about four weeks with one that may not hold either. Both figures are provider-reported.

Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.

Compare at a maintenance dose, not at signup

The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.

Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.

What neither has told us

Neither Fifty 410 nor Noom Med has named its fulfilling pharmacy or its registration class. That is true of most providers in our dataset (NexLife’s plan pages do name three 503A pharmacies), and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

The comparison that outranks both

Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.

Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.

Fifty 410 against Noom Med, lowest figure we hold by molecule
TirzepatideFifty 410 $133Noom Med $299SemaglutideFifty 410 — not capturedNoom Med $199Fifty 410Noom Med
Show this figure as a table
Data table
ItemFifty 410Noom Med
Tirzepatide$133$299
Semaglutidenot captured$199
Hatched bars mean we hold no figure at all for that molecule from that provider. A dashed edge means the figure is provider-reported rather than captured by us, so the bar is only as reliable as the provider’s own published number. A solid bar is a figure we read at the source ourselves.
Same fields, both providers
Same fields, both providers
FieldFifty 410Noom Med
Lowest captured all-in$133/mo$199/mo
Lowest tirzepatide$133/mo$299/mo
Lowest semaglutidenot verified$199/mo
Records we hold12
Evidence statusProvider-reported Provider-reportedProvider-reported Provider-reported
Fulfilling pharmacy named to usnono
Registration class disclosednono
State availability verifiednono
Cancellation terms capturednot verifiednot verified
Unverified rows are shown rather than dropped. A field omitted for one side is how a comparison picks a winner without appearing to.
Every captured record for Fifty 410 and Noom Med
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Fifty 410compoundedcompounded injectablenot recordednot verifiednot verifiednot verifiedCommitment tierProvider-reportednot recorded
Noom Medprepaidcompounded injectablenot recorded$199not verified$199Commitment tierProvider-reported2026-07-06
Noom Medprepaidcompounded injectablenot recorded$299not verified$299Commitment tierProvider-reported2026-07-06

Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.

Questions readers actually ask

Is Fifty 410 cheaper than Noom Med?

On their own pages, read November 20, 2026 or later, Fifty 410 lists $199 month to month and $149.50 at its lowest (8-week program $299); Noom Med lists $299 month to month. Month to month, like for like, Fifty 410 costs $100 a month less.

Why is one marked verified and the other reported?

On our written v4.1 scoring guide, Fifty 410 scores 65/100 (#12 of 22) and Noom Med scores 45/100 (#20 of 22). The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.

Does either name its pharmacy?

Fifty 410: ‘An independent 503A compounding pharmacy’; none named. Noom Med: No compounding pharmacy named.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Fifty 410 vs Noom Med: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/fifty-410-vs-noom-med/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4